Dr. Tiu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Landsdowne Street
Cambridge, MA 02139
Summary
- I am a physician scientist who specializes in hematology, oncology and internal medicine with more than 20 years of combined clinical and research experience in the treatment and management of patients with cancer and other medical conditions. I received my board certifications in hematology and oncology in 2010 and in internal medicine in 2006. I have extensive research experience spanning 20 years in clinical, translational and laboratory based research in both the pharmaceutical and academic settings at top medical and pharmaceutical institutions in the United States. It resulted in multiple patents, publications, and awards in the field of cancer and medicine.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010- Cleveland Clinic FoundationResidency, Internal Medicine, 2003 - 2006
University of Santo TomasClass of 2000
Certifications & Licensure
OH State Medical License 2006 - 2019
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 1 citationsClinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.Emily Nash Smyth, Jincy John, Ramon V Tiu, Melinda Dale Willard, Julie Kay Beyrer
The Oncologist. 2023-11-02 - 19 citationsOutcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versu...Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang
Transplantation and Cellular Therapy. 2023-04-01 - 83 citationsVenetoclax Plus Gilteritinib for-Mutated Relapsed/Refractory Acute Myeloid Leukemia.Naval Daver, Alexander E Perl, Joseph Maly, Mark Levis, Ellen Ritchie
Journal of Clinical Oncology. 2022-12-10
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
